科技部新竹科學園區管理局亮點投資案
安肽生醫開發新免疫治療生物藥
聯手對抗COVID-19疫情
日期：109年5月20日
聯絡人：歐瓊鎂科員
電話：(03)577-3311#2216
E-mail：mayou@sipa.gov.tw
今（2020）年新冠肺炎（COVID-19）疫情確診人數與死亡人數節節上升，癱瘓了全球醫療體系，許多國家受到嚴重影響與傷害，安肽生醫科技股份有限公司(簡稱安肽生醫)擁有篩選高專一性單株抗體的核心技術，在疫情肆虐的關鍵時期，藉由核心技術快速開發病毒抗原的專一性抗體，作為快篩檢測試劑與治療性藥物的基石，為疫情的檢測與控制貢獻一份心力。
安肽生醫是一家研發臨床治療用新穎抗體藥物與蛋白質藥物為主軸的新藥開發公司，成立於2017年，於2018年11月進駐新竹生醫園區，已發掘數十支候選抗體，並致力於開發新一代免疫治療生物藥，除了對癌細胞具有高度專一標靶作用，亦兼具免疫檢查點抑制劑的功效，可提高身體免疫系統對癌細胞的毒殺作用；針對COVID-19疫情，安肽生醫以自行設計建構的高複雜度與高效能的人類抗體庫，快速進行有關N蛋白質與S蛋白質專一性抗體開發，分別做為病毒抗原快篩檢測試劑與治療用抗體藥物開發的應用。
考量疫情嚴峻，安肽生醫期望能儘快將抗原快篩試劑提供給有需要的地區與國家，於今年3月19日與台康生技、寶齡富錦生技形成COVID-19快篩試劑聯盟的合作關係，由安肽生醫開發SARS-CoV-2病毒抗原的專一性抗體，提供給寶齡富錦前期快篩試劑開發所需的抗體，同時交付單株抗體DNA序列給台康生技，以其GMP廠的產能量產所需的單株抗體，在安肽生醫開發抗體、台康生技量產抗體及寶齡富錦開發並生產快篩檢測試劑的上中下游分工模式下，短短1個月就完成Vstrip® COVID-19快篩試劑產品，並於4月22日向台灣衛生福利部食品藥物管理署(TFDA)申請專案製造許可，預估最快5月通過驗證。
台灣在政府與人民同心齊力面對挑戰下，疫情一直控制得當，確診者在卓越的醫療水平照護下將傷害降到最低，學研單位也積極努力研發，安肽生醫以自行研發的技術積極參與，提前部署，非常振奮人心，可鼓勵民間團體一起對抗，為戰勝這次新冠病毒而努力。
Press Release
May 20, 2020
Rapid Screening Reagents Testing Kit for COVID-19 Developed by AnTaimmu BioMed Co., Ltd., Taiwan
As number of positive cases and deaths of COVID-19 pandemic is increasing at present, paralyzing global medical systems, where many countries have been seriously affected, AnTaimmu BioMed Co., Ltd., a company at the Hsinchu Biomedical Science Park, Taiwan, has endeavored to develop rapid screening reagents and therapeutic drugs to counter against the COVID-19 via its core technology in screening highly specific monoclonal antibodies.
AnTaimmu BioMed is a new drug development company that develops novel antibody drugs and protein drugs for clinical treatment, which was established in 2017 and was approved to enter the Hsinchu Biomedical Science Park in November 2018. The company has discovered dozens of candidate antibodies and is committed to development of a new generation of immunotherapy biopharmaceuticals, featuring with highly specific targeted therapeutic effects on cancer cells and immune checkpoint inhibitors, which can significantly improve the effect of body's immune system against cancer cells. For global COVID-19 pandemic, the company also develops specific antibodies for N protein and S protein in time by designing and constructing a highly complex and efficient human antibody library, which is used as a rapid screening test reagent for viral antigens and an application for the development of antibody drugs for treatment.
AnTaimmu BioMed expects to provide the antigen rapid screening reagents to regions and countries in need as soon as possible. On March 19 this year, the company formed a COVID-19 rapid screening reagent alliance with EirGenix, Inc. and Panion & BF Biotech Inc. Under the cooperative link, the specific antibody of SARS-CoV-2 virus antigen developed by AnTaimmu BioMed fills the antibody demands for early screening reagent kits of Panion & BF Biotech Inc., which then delivers the DNA sequence of the individual antibody to EirGenix, Inc. for mass production with GMP plant of EirGenix. With the wonderful labor division of these three companies, the Vstrip® COVID-19 fast screening reagent outcome was completed in just one month, and a manufacturing license was applied to the Food and Drug Administration (TFDA) of the Ministry of Health and Welfare of Taiwan on April 22, and it is estimated to pass verification in May.
Taiwan outshines other countries in countering against and controlling outbreak of the COVID-19 pandemic via collaboration between the government and civilians. Patients confirmed positive of COVID-19 in Taiwan have been cared with excellent medical resources. Academic research institutes also actively work on research and development of necessary solutions. Eager dedication and commitment of AnTaimmu BioMed in early deployment to fight against COVID-19 are very inspiring and encouraging for people not just in Taiwan but also global communities.
Media Contact
Chiung-Mei Ou,
Investment Division, Hsinchu Science Park Bureau ,MOST
Tel：(03)577-3311ext.2216
E-mail：mayou@sipa.gov.tw
